Medtronic 4Q Sales Top Forecasts, Issues FY25 Guidance
By Denny Jacob
Medtronic posted better-than-expected sales in its latest quarter on growth across its four segments and issued its guidance for the current fiscal year.
The medical technology company recorded net income of $654 million, or 49 cents a share, for the fourth-quarter ended April 26, down from $1.18 billion, or 88 cents a share, a year earlier. Adjusted earnings were $1.46 a share, above analysts' estimates of $1.45 a share.
Sales edged up 0.5% to $8.59 billion from $8.54 billion. Analysts polled by FactSet expected $8.44 billion.
Chief Executive Geoff Martha said Medtronic saw broad strength across its businesses with each of its four segments posting mid-single digit or higher organic revenue growth.
Medtronic forecast organic revenue growth in the range of 4% and 5% in fiscal 2025, as well as adjusted earnings per-share between $5.40 and $5.50. Analysts polled by FactSet expected $5.45 a share for the fiscal year.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 23, 2024 07:21 ET (11:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations